financetom
Business
financetom
/
Business
/
Canada Goose Holdings' Fiscal Q4 Adjusted Earnings, Revenue Increase; Shares Rise Pre-Bell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Canada Goose Holdings' Fiscal Q4 Adjusted Earnings, Revenue Increase; Shares Rise Pre-Bell
May 16, 2024 5:05 AM

07:37 AM EDT, 05/16/2024 (MT Newswires) -- Canada Goose Holdings ( GOOS ) reported fiscal Q4 adjusted earnings Thursday of 0.19 Canadian dollars ($0.14) per diluted share, up from CA$0.13 a year earlier.

Analysts polled by Capital IQ expected CA$0.06.

Revenue for the quarter ended March 31 was CA$358 million, up from CA$293.2 million a year earlier.

Analysts surveyed by Capital IQ expected CA$316.3 million.

For fiscal 2025, the company said it expects non-IFRS adjusted net income per share to grow by a mid-teen percentage year-over-year. Revenue for the fiscal year is projected to grow in the low-single-digits year-over-year.

Shares of the company rose more than 14% in recent premarket activity on Thursday.

Price: 13.10, Change: +1.68, Percent Change: +14.71

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Magyar Bancorp Board Approves Share Buyback Plan
Magyar Bancorp Board Approves Share Buyback Plan
May 26, 2025
05:40 PM EDT, 05/22/2025 (MT Newswires) -- Magyar Bancorp ( MGYR ) said Thursday that its board authorized a stock repurchase program to repurchase up to 5% of the company's outstanding shares, or up to 323,547 shares. The company said it has completed its previous stock repurchase program, authorized on Dec. 8, 2022, by repurchasing 337,146 shares. ...
Regeneron Pharmaceuticals Reveals Trial Data of Drug Combination to Treat Multiple Myeloma
Regeneron Pharmaceuticals Reveals Trial Data of Drug Combination to Treat Multiple Myeloma
May 26, 2025
05:40 PM EDT, 05/22/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said late Thursday its initial phase 1b trials data of linvoseltamab in combination with carfilzomib or bortezomib to treat refractory multiple myeloma showed a 90% objective response rate after a 15-month follow-up. Almost 76% of patients achieved a complete response, the company said. Adverse events were recorded in...
White House 'MAHA' report calls out food, chemicals impact on children's health
White House 'MAHA' report calls out food, chemicals impact on children's health
May 26, 2025
* MAHA report criticizes highly processed foods and additives in American diet * It does not call for specific regulatory changes or policies * Farm group have warned that further regulation could hurt food production (Adds Trump comment in paragraph 3; outside scientist in paragraphs 7-8; MAHA activist comment in paragraphs 9-10) By Leah Douglas, Michael Erman and Renee Hickman...
Copart misses third-quarter profit estimates on lower vehicle sales, higher expenses
Copart misses third-quarter profit estimates on lower vehicle sales, higher expenses
May 26, 2025
May 22 (Reuters) - Copart ( CPRT ) reported third-quarter revenue and net income below Wall Street estimates on Thursday, as weak vehicle sales and higher expenses offset growth in its services segment. Shares of the company, which primarily provides auction services to sell damaged and total-loss vehicles to used-car dealers and dismantlers, dropped as much as 4.3% after the...
Copyright 2023-2025 - www.financetom.com All Rights Reserved